Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing

Journal of Neuro-Oncology

Volumn 35, Issue 1, 1997, Pages 47-53

  Forsyth, Peter A ^a,c,d   Balmaceda, Casilda ^a,e   Peterson, Kendra ^a,f   Seidman, Andrew D ^a   Brasher, Penny ^b   DeAngelis, Lisa M ^a,g  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b TOM BAKER CANCER CENTRE   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e New York State Psychiat Inst and New York Presbyterian Hospital Columbia University Medical Center   (United States)

^f STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Neurologic complication; Paclitaxel; Peripheral neuropathy

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; NEUROLOGIC DISEASE; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; RISK FACTORS; SENSORY THRESHOLDS;

EID: 0030839691     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005805907311     Document Type: Article

References (44)

1. McGuire WP, Rowinsky EK, Rosenheim NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC: Taxol: A unique antineoplastic agent with significant activity in advanced epithelial neoplasms. Ann Int Med 111: 273-279, 1989
2. Thigpen T, Blessing J, Ball H, Hummel S, Barret R: Phase 2 trial of Taxol as a second-line therapy for ovarian carcinoma: A Gynecologic Oncology Group Study (Abstract). Proc Amer Soc Clin Oncol 9: 156, 1990
3. Schiff PB, Horowitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci 77: 1561-1565, 1980
4. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259, 1990
5. Bogdan C, Ding A: Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol 52: 119-121, 1992
6. Wiernik PH, Schwartz EL, Enzig A, et al.: Phase 1 trial of Taxol given as a 24-hr infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 5: 1232-1239, 1987b.
7. Sarosy G, Kohn E, Stone DA, et al.: Phase 1 study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10: 1165-1170, 1992
8. Schiller JH, Storer B, Tutsch K, et al.: Phase 1 trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12: 241-248, 1994
9. Rowinsky EK, Chaudry V, Forastiere AA, et al.: Phase 1 and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010-2020, 1993
10. Chaudry V, Rowinsky EK, Sartorius SE, et al.: Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: Clinical and electrophysiologic studies. Ann Neurol 35: 304-311, 1994
11. Arezzo JC, Schaumburg HH, Petersen CA : Rapid screening for peripheral neuropathy: A field study with the Optacon. Neurology 33: 626-629, 1983
12. Bove F, Litwak MS, Arezzo JC, Baker EL: Quantitative sensory testing in occupational medicine. Semin Occupat Med 1: 185-189, 1986
13. Rendell MS, Katims JJ, Richter R, Rowland F: A comparison of nerve conduction velocities and current perception thresholds as correlates of clinical severity of diabetic sensory neuropathy. J Neurol Neurosurg Psychiat 52: 502-511, 1989
14. Gulevich SJ, Kalmijn JA, Thal LJ, et al.: Sensory testing in human immunodeficiency virus type 1 infected men. Arch Neurol 49: 1281-1284, 1992
15. Redmond JMT, McKenna MJ, Feingold M, Ahmad BK: Sensory testing versus nerve conduction velocity in diabetic polyneuropathy. Muscle & Nerve 15: 1334-1339, 1992
16. Consensus report from the Peripheral Neuropathy Association: Quantitative sensory testing: A consensus report from the Peripheral Neuropathy Association. Neurology 43: 1050-1052, 1993
17. Verdugo R, Ochoa JL: Quantitative somatosensory thermotest. Brain 115: 893-913, 1992
18. Peterson K, Forsyth P, Posner JB: Paraneoplastic sensorimotor polyneuropathy in patients with breast cancer. J Neuro-Oncol 21: 159-170, 1994
19. Donehower RC, Rowinsky EK, Grochow LB, et al.: Phase 1 trial of Taxol in patients with advanced cancer. Cancer Treat Rep 71: 1171-1177, 1987
20. Brown T, Havlin K, Weiss G, et al.: A phase 1 trial of Taxol given by a six hour intravenous infusion. J Clin Oncol 9: 1261-1267, 1991
21. ten Bokkel Huinink WW, Eisenhauer E, Swenerton K: Preliminary evaluation of a multicenter, randomized comparative study of Taxol (paclitaxel) dose and infusion length in platinum treated ovarian cancer. Cancer Treat Rev 19 (Suppl C): 79-86, 1993
22. Wiernik PH, Schwartz EL, Strauman JJ, et al.: Phase 1 clinical and pharmacokinetic study of Taxol. Cancer Res 47: 2486-2493, 1987a
23. Postma TJ, Liefting AJM, Heimans JJ, et al.: Neurotoxicity in patients with breast cancer (BC) and ovarian cancer (OV) treated with Taxol (Abstract). Proc Amer Soc Clin Oncol 12: 64, 1993
24. Legha SS, Tenney DM, Krakoff IR: Phase I study of Taxol using a 5-day intermittent schedule. J Clin O ncol 4: 762-766, 1986
25. Seidman A, Reichman B, Crown J, et al.: Taxol as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13: 1152-1159, 1995
26. Reichman BS, Seidman AD, Crown JPA, et al.: Taxol and recombinant human granulocyte colony-stimulating factors as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943-1951, 1991
27. Einzig AI, Hochster H, Wiernik PH, et al.: A phase 2 study of Taxol in metastatic melanoma. Invest New Drugs 9: 59-64, 1991a
28. Einzig AI, Gorowski E, Sasloff J, et al.: Phase 2 trial of Taxol in patients with metastatic renal cell carcinoma. Cancer 9: 133-136, 1991b
29. Einzig AI, Wiernik PH, Sasloff J: Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10: 1748-1753, 1992
30. Chang A, Kim K, Glick J, et al.: Phase 2 study of Taxol in patients with stage 4 non-small cell lung cancer: ECOG Results (Abstract). Proc Amer Soc Clin Oncol 11: 293, 1992
31. Kohn EC, Sarosy G, Bicher A, et al.: Dose-intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86: 18-24, 1994
32. Peterson ER, Crain SM: Nerve growth factor attenuates neurotoxic effects of Taxol on spinal cord-ganglion explants from fetal mice. Science 217: 377-379, 1982
33. Apfel SC, Lipton RB, Arrezo JC, et al.: Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 29: 87-90, 1991
34. Rowinsky EK, Gilbert MR, McGuire WP, et al.: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9: 1692-1703, 1991
35. van Gerven JMA, Moll JWB, van den Bent MJ, et al.: Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 30A: No. 8, 1074-1077, 1994
36. Kaplan JG, Einzig AI, Schaumburg HH: Taxol causes permanent large fiber peripheral nerve dysfunction: A lesson for preventative strategies. J Neuro-Oncol 16: 105-107, 1993
37. Holmes FA, Walter RS, Theriault RL, et al.: Phase 2 trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991
38. Trimble EL, Adams JD, Vena D, Hawkins MJ, et al.: Taxol for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11: 2405-2410, 1993
39. Lipton RB, Apfel SC, Dutcher JP, et al.: Taxol produces a predominantly sensory neuropathy. Neurology 39: 368-373, 1989
40. Sahenk Z, Barohn R, New P, et al.: Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Arch Neurol 51: 726-729, 1994
41. Donehower RC, Rowinsky EK: An overview of experience with Taxol (paclitaxel) in the USA. Cancer Treat Rev 19 (Suppl C): 63-78, 1993
42. 2. J Clin Oncol 12: 1741-1742, 1994
43. Capri E, Munzone E, Tarenzi, Fulfaro, Gianni L: Optic nerve disturbances: A new form of paclitaxel neurotoxicity. J Natl Cancer Inst 86: 1099-1101, 1994
44. Siegal T, Haim N: Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer 66: 1117-1123, 1990